28
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          To examine the differential diagnostic significance of cerebrospinal fluid (CSF) biomarkers reflecting Alzheimer’s disease-related amyloid β (Aβ) production and aggregation, cortical neuronal damage, tau pathology, damage to long myelinated axons and astrocyte activation, which hypothetically separates patients with idiopathic normal pressure hydrocephalus (iNPH) from patients with other neurodegenerative disorders.

          Methods

          The study included lumbar CSF samples from 82 patients with iNPH, 75 with vascular dementia, 70 with Parkinson’s disease, 34 with multiple system atrophy, 34 with progressive supranuclear palsy, 15 with corticobasal degeneration, 50 with Alzheimer’s disease, 19 with frontotemporal lobar degeneration and 54 healthy individuals (HIs). We analysed soluble amyloid precursor protein alpha (sAPPα) and beta (sAPPβ), Aβ species (Aβ38, Aβ40 and Aβ42), total tau (T-tau), phosphorylated tau, neurofilament light and monocyte chemoattractant protein 1 (MCP-1).

          Results

          Patients with iNPH had lower concentrations of tau and APP-derived proteins in combination with elevated MCP-1 compared with HI and the non-iNPH disorders. T-tau, Aβ40 and MCP-1 together yielded an area under the curve of 0.86, differentiating iNPH from the other disorders. A prediction algorithm consisting of T-tau, Aβ40 and MCP-1 was designed as a diagnostic tool using CSF biomarkers.

          Conclusions

          The combination of the CSF biomarkers T-tau, Aβ40 and MCP-1 separates iNPH from cognitive and movement disorders with good diagnostic sensitivity and specificity. This may have important implications for diagnosis and clinical research on disease mechanisms for iNPH.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders.

          As there are no biological markers for the antemortem diagnosis of degenerative parkinsonian disorders, diagnosis currently relies upon the presence and progression of clinical features and confirmation depends on neuropathology. Clinicopathologic studies have shown significant false-positive and false-negative rates for diagnosing these disorders, and misdiagnosis is especially common during the early stages of these diseases. It is important to establish a set of widely accepted diagnostic criteria for these disorders that may be applied and reproduced in a blinded fashion. This review summarizes the findings of the SIC Task Force for the study of diagnostic criteria for parkinsonian disorders in the areas of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration. In each of these areas, diagnosis continues to rest on clinical findings and the judicious use of ancillary studies. Copyright 2003 Movement Disorder Society
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2-/- mice.

              Cerebral inflammation involves molecular cascades contributing to progressive damage after traumatic brain injury (TBI). The chemokine CC ligand-2 (CCL2) (formerly monocyte chemoattractant protein-1, MCP-1) is implicated in macrophage recruitment into damaged parenchyma after TBI. This study analyzed the presence of CCL2 in human TBI, and further investigated the role of CCL2 in physiological and cellular mechanisms of secondary brain damage after TBI. Sustained elevation of CCL2 was detected in the cerebrospinal fluid (CSF) of severe TBI patients for 10 days after trauma, and in cortical homogenates of C57Bl/6 mice, peaking at 4 to 12 h after closed head injury (CHI). Neurological outcome, lesion volume, macrophage/microglia infiltration, astrogliosis, and the cerebral cytokine network were thus examined in CCL2-deficient (-/-) mice subjected to CHI. We found that CCL2-/- mice showed altered production of multiple cytokines acutely (2 to 24 h); however, this did not affect lesion size or cell death within the first week after CHI. In contrast, by 2 and 4 weeks, a delayed reduction in lesion volume, macrophage accumulation, and astrogliosis were observed in the injured cortex and ipsilateral thalamus of CCL2-/- mice, corresponding to improved functional recovery as compared with wild-type mice after CHI. Our findings confirm the significant role of CCL2 in mediating post-traumatic secondary brain damage.
                Bookmark

                Author and article information

                Journal
                J Neurol Neurosurg Psychiatry
                J. Neurol. Neurosurg. Psychiatry
                jnnp
                jnnp
                Journal of Neurology, Neurosurgery, and Psychiatry
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                0022-3050
                1468-330X
                October 2019
                5 June 2019
                : 90
                : 10
                : 1117-1123
                Affiliations
                [1 ] departmentHydrocephalus Research Unit, Department of clinical neuroscience , Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg , Gothenburg, Sweden
                [2 ] departmentDepartment of Clinical Neuroscience , Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg , Gothenburg, Sweden
                [3 ] departmentDepartment of Psychiatry and Neurochemistry , Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg , Gothenburg, Sweden
                [4 ] departmentClinical Neurochemistry Laboratory , Sahlgrenska University Hospital , Mölndal, Sweden
                [5 ] departmentDepartment of Neurodegenerative Disease , UCL Institute of Neurology , London, UK
                [6 ] UK Dementia Research Institute at UCL , London, UK
                [7 ] departmentUnit of Clinical Neuroscience, Neurology , University of Oulu , Oulu, Finland
                [8 ] departmentMedical Research Center , Oulu University Hospital , Oulu, Finland
                [9 ] departmentDepartment of Neurology , Kuopio University Hospital and University of Eastern Finland , Kuopio, Finland
                [10 ] departmentDepartment of Pathology , Kuopio University Hospital and University of Eastern Finland , Kuopio, Finland
                [11 ] departmentDepartment of Acute Internal Medicine and Geriatrics , Linköping University , Linköping, Sweden
                [12 ] departmentUnit of Clinical Neuroscience, Neurosurgery , University of Oulu , Oulu, Finland
                [13 ] departmentDepartment of Neurosurgery , Kuopio University Hospital and University of Eastern Finland , Kuopio, Finland
                Author notes
                [Correspondence to ] Dr Anna Jeppsson, Department of Clinical Neuroscience, University of Gothenburg Institute of Neuroscience and Physiology, Goteborg 405 30, Sweden; anna.jeppsson@ 123456gu.se
                Author information
                http://orcid.org/0000-0002-5908-1904
                http://orcid.org/0000-0003-4997-5266
                Article
                jnnp-2019-320826
                10.1136/jnnp-2019-320826
                6817981
                31167811
                008d19d5-3607-4e18-a6b3-d04dce9a873c
                © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:  http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 18 March 2019
                : 29 April 2019
                : 12 May 2019
                Funding
                Funded by: Kuopio University Hospital VTR-fund;
                Funded by: FundRef http://dx.doi.org/10.13039/501100003792, Hjärnfonden;
                Award ID: #FO2017-0243
                Funded by: Swedish Alzheimer Foundation;
                Award ID: #AF-742881
                Funded by: FundRef http://dx.doi.org/10.13039/501100004359, Vetenskapsrådet;
                Award ID: #2017-00915
                Funded by: Swedish State under the agreement between the Swedish government and the country councils, the ALF agreement;
                Award ID: 2017-04961
                Award ID: ALFBGB-720121
                Award ID: ALFGBG-715986
                Award ID: ALFGBG-720931
                Categories
                General Neurology
                1506
                Research paper
                Custom metadata
                unlocked

                Surgery
                idiopathic normal pressure hydrocephalus,alzheimer’s disease,parkinson’s disease,multiple systems atrophy,progressive supranuclear palsy,corticobasal degeneration,frontotemporal dementia,vascular dementia,biomarkers,csf

                Comments

                Comment on this article